Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
The modeling and simulation solutions provider Simulations Plus has been contracted to support countermeasure development for acute radiation syndrome in a partnership with a global pharma company.
